Epstein Secrets

230 Requirements) CONFIDENTIAL I WTAS LLC EFTA00307397 WTAS ALIPHCOM — COMMON EQUITY VALUATION REPORT As of June 20, 2011 August 3, 2011 Mr. Michael Tamaru Chief Financial Officer AliphCom 99 Rhode Island Street, 3 ni floor San Francisco, CA 94103 Dear Mr. Tamaru: We have completed our analysis of

median discounts from the restricted stock studies. SUMMARY OF RESTRICTED STOCK STUDIES [SEC Studies (non-reporting OTC companies [Gelman Study [Moroney Study $Maher Study [Trout Study [Standard Research Consultants Study [Silber Study [Management Planning, Inc. Study [FMV Study [Hertzel - Smith Stud

230 Requirements) CONFIDENTIAL I WTAS LLC EFTA00307296 WTAS ALIPHCOM — COMMON EQUITY VALUATION REPORT As of June 20, 2011 August 3, 2011 Mr. Michael Tamaru Chief Financial Officer AliphCom 99 Rhode Island Street, 3 ni floor San Francisco, CA 94103 Dear Mr. Tamaru: We have completed our analysis of

median discounts from the restricted stock studies. SUMMARY OF RESTRICTED STOCK STUDIES [SEC Studies (non-reporting OTC companies [Gelman Study [Moroney Study $Maher Study [Trout Study [Standard Research Consultants Study [Silber Study [Management Planning, Inc. Study [FMV Study [Hertzel - Smith Stud

230 Requirements) CONFIDENTIAL I WTAS LLC EFTA00307195 WTAS ALIPHCOM — COMMON EQUITY VALUATION REPORT As of June 20, 2011 August 3, 2011 Mr. Michael Tamaru Chief Financial Officer AliphCom 99 Rhode Island Street, 3 ni floor San Francisco, CA 94103 Dear Mr. Tamaru: We have completed our analysis of

median discounts from the restricted stock studies. SUMMARY OF RESTRICTED STOCK STUDIES [SEC Studies (non-reporting OTC companies [Gelman Study [Moroney Study $Maher Study [Trout Study [Standard Research Consultants Study [Silber Study [Management Planning, Inc. Study [FMV Study [Hertzel - Smith Stud